Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drugs in R&D
Erschienen in: Drugs in R&D 2/2008

01.03.2008 | Adis R&D Profile

Faropenem Medoxomil

A0026, BAY 56-6854, BAY 566854, Faropenem Daloxate, SUN 208, SUN A0026

Erschienen in: Drugs in R&D | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Excerpt

Replidyne is developing faropenem medoxomil, the ester-type prodrug of faropenem, for the treatment of bacterial infections and respiratory tract infections, including acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP). Faropenem medoxomil is also being developed for the treatment of tonsillitis, pharyngitis and otitis media in children. …
Literatur
1.
2.
3.
4.
Forest Laboratories Inc, Replidyne Inc. Forest Laboratories Announces Termination of Agreement for Faropenem. Media Release: 6 Feb 2007. Available from URL: http://​www.​frx.​com
5.
Replidyne Inc, Forest Laboratories Holdings Ltd. Replidyne and Forest Laboratories Announce Faropenem Medoxomil Licensing Agreement. Media Release: 13 Feb 2006. Available from URL: http://​www.​replidyne.​com
6.
7.
8.
Replidyne Inc. Replidyne Submits New Drug Application (NDA) for Orapem(TM) (Faropenem Medoxomil) to U.S. Food and Drug Administration. Media Release: 9 Jan 2006. Available from URL: http://​www.​replidyne.​com
9.
Forest Laboratories Inc, Replidyne Inc. Replidyne and Forest Laboratories Announce FDA Acceptance for Review of New Drug Application for Oral Antibiotic Faropenem Medoxomil. Media Release: 23 Feb 2006. Available from URL: http://​www.​frx.​com
10.
11.
12.
13.
Deisseroth AB, Hanania EG, Fu S. Genetic therapy of human disease. Bone Marrow Transplantation 15 (Suppl. 1): 285–290, 1995
14.
Voith B, Schuehly U, Voigt U, et al. Influence of food intake on the pharmacokinetics, safety and tolerability of a single dose of faropenem daloxate. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy: 16, 17 Sep 2000
15.
Schmidt A, voith B, Dalhoff A. No evidence of active metabolites of faropenem. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 23 (plus poster), 22 Sep 2001
16.
Voith B, Wilding I, Wray A, et al. Absorption of faropenem daloxate delivered locally to different sites of the gastrointestinal tract by an Enterion capsule. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 23 (plus poster), 22 Sep 2001
17.
Gill SC, Tosiello R. Pharmacokinetics of faropenem following oral administration of faropenem medoxomil in association with thorough QT/QTc evaluation. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy: 29 (plus poster) abstr. A-1942, 27 Sep 2006
18.
Tosiello R, Sprenger C, Echols R, et al. A thorough ECG study of faropenem medoxomil compared to placebo and a positive control. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy: 24–25 (plus poster) abstr. A1111, 27 Sep 2006
19.
Nakashima M, Umemura K. Pharmacokinetics of SUN208 in healthy male volunteers. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 136, 17 Sep 1995
20.
Nagelschmitz J, Koch M, Heizmann WR, et al. Effect of multiple dose treatments with faropenem daloxate in comparison to amoxicillin/clavulanic acid on the normal fecal and oropharyngeal flora of healthy subjects. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: 22 (plus poster), 22 Sep 2001
21.
Marbury T, Roesch B, Corrado M, et al. A double-blind, randomized, dose ranging study to evaluate the safety of faropenem medoxomil at 300 or 600 mg BID for seven days in healthy volunteers. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy: 396 (plus poster) abstr. L-480, 17 Sep 2007
22.
Kowalsky S, Upchurch J, Rosemore M, et al. Prospective, randomized, double-blind, three-armed, multicenter, comparative trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO, BID for 7 days versus faropenem daloxate 300 mg PO, BID for 10 days versus cefuroxime axetil 250 mg PO, BID for 10 days in the treatment of acute bacterial sinusitis. Study 100288. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 389 (plus poster) abstr. L-575, Dec 2005
23.
Echols R, Tlili N, Nikolaidis P, et al. Prospective, randomized, double-blind, multinational, multicenter clinical trial comparing the efficacy and safety of faropenem daloxate 300 mg PO, BID for 7 days with cefuroxime axetil for 7 days (250 mg BID) in the treatment of patients with acute bacterial sinusitis. Study 10186. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 388–389, Dec 2005
24.
Siegert R, Berg O, Gehanno P, et al. Faropenem daloxate vs. cefuroxime axetil in the treatment of acute sinusitis. Clinical Microbiology and Infection 8 (Suppl. 1): 327, Apr 2002
25.
Dhillon G, Williams H, Corrado M, et al. A phase II double-blind, randomized trial comparing faropenem medoxomil at 300 mg BID for seven days and 600 mg BID for five days in subjects with acute maxillary sinusitis diagnosed by antral tap. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy: 396 (plus poster) abstr. L-481, 17 Sep 2007
26.
Echols R, Schürmann D. A multicenter, multinational, prospective, randomized, double-blind study to compare the efficacy and safety of faropenem daloxate 300 mg PO BID for 10 days with co-amoxiclav 500/125 mg PO TID for 10 days in the treatment of adult patients with community-acquired pneumonia. Study 10189. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 393–394 (plus oral presentation) abstr. L708, Dec 2005
27.
Drehobl M, Patel T, Echols R. Prospective, randomized, double-blind study comparing faropenem daloxate 300 mg PO BID for 10 days with cefpodoxime 200 mg PO BID for 14 days in the treatment of patients with community-acquired pneumonia. Study 100290. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 388 (plus poster) abstr. L-571, Dec 2005
28.
Walker G, Upchurch J, Fogarty C, et al. Prospective, randomized, double-blind study comparing faropenem daloxate 300 mg PO BID for 5 days with azithromycin for 5 days (500 mg PO OD on day 1, then 250 mg PO OD on day 2 through 5) in the treatment of patients with acute exacerbation of chronic bronchitis. Study 100291. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 389 (plus poster) abstr. L-576, Dec 2005
29.
Corrado M, Echols R. A multinational, multi-centre, prospective, double-blind, parallel group, randomized study of faropenem daloxate (BAY 56-6854) oral tablets compared to clarithromycin oral tablets, in the treatment of acute exacerbation of chronic bronchitis. Study 10187. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 388 (plus poster) abstr. L-572, Dec 2005
30.
Richard G, Mazzone F, Drehobl M, et al. Prospective, randomized, double-blind study comparing faropenem daloxate 300 mg PO BID for 5 days with trimethoprim/sulfamethoxazole 160/800 mg PO bid for 5 days in treatment of patients with acute, uncomplicated lower urinary tract infections. Study 100286. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 411, Dec 2005
31.
Davis A, Heaton K, Huck W, et al. Prospective, randomized, double-blind, multi-center trial to compare the efficacy and safety of faropenem daloxate 300 mg PO BID for 5 days versus penicillin VK 500 mg PO TID for 10 days in the treatment of adults and adolescents with acute Streptococcus pyogenes tonsillitis/pharyngitis. Study 100293. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 392, Dec 2005
32.
Corrado M, Shemer A, Echols R. Prospective, randomized, double-blind, double-dummy, multi-centre comparative trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO BID for 7 days vs co-amoxiclav 625 mg PO TID for 7 days in the treatment of uncomplicated skin and skin structure infections. Study 10190. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 402 (plus poster) abstr. L-1572, Dec 2005
33.
Huck W, Heaton K, Elliott S, et al. Prospective, randomized, double-blind, multicenter, comparative trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO BID for 7 days versus cephalexin 500 mg PO BID for 7 days in the treatment of uncomplicated skin and skin structure infections. Study 100292. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 402 (plus poster) abstr. L-1571, Dec 2005
34.
Schuehly U, Voith B, Voigt U, et al. Investigation of a potential pharmacokinetic interaction between furosemide and faropenem daloxate after concomitant single-dose administration. Clinical Microbiology and Infection 7 (Suppl. 1): 274–275, 2001
35.
Voith B, Schuehly U, Ruf T, et al. Influence of concomitant administration of probenecid on the safety, tolerability, and pharmacokinetics of a single dose of faropenem daloxate. Clinical Microbiology and Infection 7 (Suppl. 1): 274, 2001
36.
Voith B, Schuehly U, Ruf T, et al. Influence of a pre- and cotreatment with Maalox (Rm) 70 on safety, tolerability, and pharmacokinetics of a single dose of faropenem daloxate. Clinical Microbiology and Infection 7 (Suppl. 1): 274, 2001
37.
Heine H, Rubino CM, Basett J, et al. Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine-Bacil-lus anthracis inhalation post-exposure prophylaxis model. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy: 34 (plus poster) abstr. A-1435, 17 Sep 2007
38.
Heine HS, Miller L, Bassett J, et al. Activity of faropenem against Bla1 and Bla2 beta-lactamase producing strains of Bacillus anthracis. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy: 178 (plus poster) abstr. E-226, 27 Sep 2006
39.
Young C, Critchley IA, Janjic N. Activity of faropenem against multi-drug resistant Streptococcus pneumoniae identified in phase III respiratory clinical trials and correlation with clinical microbiological success. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy: 178 (plus poster) abstr. E-224, 27 Sep 2006
40.
Clawson Stone K, Dagan R, Arguedas A, et al. Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy: 178 (plus poster) abstr. E-225, 27 Sep 2006
41.
Singh S, Echols R. Prospective, multi-center, nonblind, uncontrolled trial to evaluate the efficacy and safety of faropenem daloxate 300 mg PO, BID for 7 days in the treatment of acute bacterial sinusitis. Study 100287. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: 389 (plus poster) abstr. L-574, Dec 2005
Metadaten
Titel
Faropenem Medoxomil
A0026, BAY 56-6854, BAY 566854, Faropenem Daloxate, SUN 208, SUN A0026
Publikationsdatum
01.03.2008
Verlag
Springer International Publishing
Erschienen in
Drugs in R&D / Ausgabe 2/2008
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI
https://doi.org/10.2165/00126839-200809020-00005

Weitere Artikel der Ausgabe 2/2008

Drugs in R&D 2/2008 Zur Ausgabe

Original Research Article

Preclinical Efficacy and Safety Pharmacology of SUN-1334H, a Potent Orally Active Antihistamine Agent

Review Article

Difficulties in the Production of Identical Drug Products from a Pharmaceutical Technology Viewpoint

Original Research Article

ATP Production and TCA Activity are Stimulated by Propionyl-L-Carnitine in the Diabetic Rat Heart

Adis R&D Profile

Mepolizumab

Review Article

Microdosing Studies in Humans

Adis R&D Profile

Mifamurtide